原发性醛固酮增多症肾上腺切除术前使用盐皮质激素受体拮抗剂
本研究基于SPAIN-ALDO注册队列,回顾性分析355例单侧原发性醛固酮增多症肾上腺切除患者,其中273例(76.9%)术前接受MRA治疗。
要点
- 术前MRA治疗可安全控制血压和血钾,不增加术后并发症风险。
- 长期随访中,术前MRA治疗与更高的生化完全缓解率独立相关。
- 需注意预处理患者高血压病程更长、低钾血症更常见、醛固酮浓度更高。
核心结论
- 术前MRA治疗可安全用于等待手术的单侧原发性醛固酮增多症患者,不增加术后高钾血症、低醛固酮血症、肾功能损害或低血压风险。
- 术前MRA治疗与长期术后生化完全缓解率更高独立相关。
研究设计与样本
- 基于SPAIN-ALDO注册队列的回顾性分析,纳入355例因单侧原发性醛固酮增多症接受肾上腺切除术的患者。
- 比较术前接受MRA治疗(n=273,76.9%)与未接受MRA治疗(n=82)患者的术后并发症和手术结局。
主要发现
- 预处理组与未预处理组在术后30天内和90天内的术后高钾血症、低醛固酮血症、肾功能损害、血压变化和生化结局方面无差异。
- 多变量分析显示,术前使用MRA与术后生化成功缓解独立相关。
临床怎么用
- 对于等待肾上腺切除术的单侧原发性醛固酮增多症患者,可术前使用MRA控制血压和血钾水平。
- 术前MRA治疗不增加术后高钾血症、低醛固酮血症、肾功能损害或低血压风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Perioperative use of mineralocorticoid receptor antagonists (MRA) in patients with unilateral primary aldosteronism (PA) awaiting surgery is not well standardized. OBJECTIVE: The aim of this study was to compare the risk of postoperative complications and surgical outcomes between PA patients treated with MRA prior to adrenalectomy and those not pretreated. METHODS: Adrenalectomized patients for unilateral PA from the SPAIN-ALDO registry, with clinical, hormonal, and treatment information before and after adrenalectomy, were analyzed. RESULTS: A total of 355 surgically treated patients were included; 76.9% (n = 273) received presurgical treatment with MRA (spironolactone [64.5%], eplerenone [35.5%]). Adrenalectomy was guided by lateralization at adrenal venous sampling in 33.5% of the overall cohort, and by imaging in all the other cases. Patients pretreated with MRA had longer duration of hypertension, higher prevalence of hypokalemia, and greater aldosterone concentrations than those not pretreated (n = 82). No differences in the rate of postsurgical hyperkalemia, hypoaldosteronism, renal function impairment, blood pressure changes, and biochemical outcomes were detected between groups in the immediate (≤30 days) and short-term (≤90 days) follow-up evaluations after surgery. At long-term follow-up (≥6 months), patients pretreated with MRA exhibited better postsurgical biochemical outcomes (81.7% had complete biochemical response vs 57.1% of non-pretreated patients; P = .004). In the multivariable analysis, the use of MRA prior to adrenalectomy was independently associated with a successful postsurgical biochemical response. CONCLUSION: Preoperative MRA therapy can be safely introduced to control blood pressure and potassium levels in patients with PA awaiting surgery, without increasing the risk of postoperative hyperkalemia, hypoaldosteronism, renal impairment, or hypotension.
引用
- Goi J, Paja Fano M, Rizo Gellida A, et al. Mineralocorticoid Receptor Antagonist Pre-Adrenalectomy in Primary Aldosteronism. J Clin Endocrinol Metab. 2026. PMID: 41045519. doi:10.1210/clinem/dgaf545
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。